Evidence map›Paper›PMID 42648293›Full record

ArticleCell host & microbe2026

Defined human Clostridia consortia reverse colitis via dual effects of tryptophan metabolites on microbiota and immunity.

Akihiko Oka, Gerold Bongers, Yoshiyuki Mishima, Andrew J Baltus, Simon M Gray, Bo Liu, Jeremy W Herzog, John R Benedetto, Ting-Jia Fan, Jisun Jang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell host & microbe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Akihiko OkaCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Internal Medicine II, Shimane University Faculty of Medicine, Izumo, Shimane 693-8501, Japan.
Gerold BongersJohnson & Johnson, Spring House, PA 19477, USA.
Yoshiyuki MishimaCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Internal Medicine II, Shimane University Faculty of Medicine, Izumo, Shimane 693-8501, Japan.
Andrew J BaltusJohnson & Johnson, Spring House, PA 19477, USA.
Simon M GrayCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Bo LiuCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Jeremy W HerzogCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
John R BenedettoThe National Gnotobiotic Rodent Resource Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Ting-Jia FanCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Jisun JangCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Internal Medicine, Veterans Health Service Medical Center, Seoul 05368, Korea.
Muyiwa AwoniyiCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Digestive Disease Institute, Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH 44195, USA.
Esmat RoustaCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Ling-Yang HaoJohnson & Johnson, Spring House, PA 19477, USA.
Raad Z GharaibehDepartment of Medicine, Division of Gastroenterology, University of Florida, Gainesville, FL 32608, USA; Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32608, USA.
Anthony A FodorDepartment of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Toshifumi OhkusaDepartment of Microbiota Research, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-0033, Japan.
Koji AtarashiDepartment of Microbiology and Immunology, Human Biology Microbiome Quantum Research Center (WPI-Bio2Q), Keio University, Shinjuku-ku, Tokyo, 160-8582, Japan; RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan.
Shinji FukudaInstitute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata 997-0052, Japan; Gut Environmental Design Group, Kanagawa Institute of Industrial Science and Technology, Kanagawa 210-0821, Japan; Transborder Medical Research Center, University of Tsukuba, Ibaraki 305-8575, Japan; Innovative Microbiome Therapy Research Center, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan.
Kenya HondaDepartment of Microbiology and Immunology, Human Biology Microbiome Quantum Research Center (WPI-Bio2Q), Keio University, Shinjuku-ku, Tokyo, 160-8582, Japan; RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan.
Lani R San MateoJohnson & Johnson, Spring House, PA 19477, USA.
R Balfour SartorCenter for Gastrointestinal Biology and Disease, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; The National Gnotobiotic Rodent Resource Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: rbs@med.unc.edu.

Funding

PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
Role of IL-10 in APC Regulation of Protective vs. Pathogenic T Cell Responses toP01DK094779 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SARTOR, RYAN B · 2013 to 2023
$17.9M
National Gnotobiotic Rodent Resource CenterP40OD010995 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ryan B Sartor · 2012 to 2026
$9.7M
GASTROENTEROLOGY RESEARCH TRAININGT32DK007737 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHEHZAD Z. SHEIKH · 1996 to 2026
$7.8M
BASIC IMMUNE MECHANISMST32AI007273 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TISCH, ROLAND M · 1985 to 2020
$5.6M
Immunologic and Microbial Mechanisms of Inflammatory Bowel Diseases Therapy FailureK08DK144596 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Simon Matthew Gray · 2025 to 2026
$343k
NIAID NIH HHS T32 AI007273NIDDK NIH HHS K08 DK144596NIDDK NIH HHS P01 DK094779NIDDK NIH HHS P30 DK034987NIDDK NIH HHS T32 DK007737NIH HHS P40 OD010995
6 · The paper itself

Abstract

Microbial dysbiosis and disrupted mucosal immune homeostasis are integrally involved in the pathogenesis of inflammatory bowel diseases (IBDs). Live biotherapeutic products (LBPs) offer a potential therapeutic strategy to restore beneficial microbes and mitigate disease. We investigated the therapeutic efficacy of 2 LBPs, human Clostridia consortia 17-mix and 11-mix, by treating established colitis in murine models. Both LBPs exhibited therapeutic effects in T cell-mediated chronic colitis models induced by human microbiota and in pathobiont-driven gnotobiotic colitis models established with combinations of IBD-relevant human-derived strains. Metagenomic and metabolomic analyses elucidated mechanisms that go beyond established functions driven by short-chain fatty acids (SCFAs) and interleukin (IL)-10-producing regulatory T cells. Notably, LBPs exerted therapeutic effects by directly inhibiting resident pathobionts and through IL-10-independent activation of host anti-inflammatory aryl hydrocarbon receptor (AhR) pathways by bacterial tryptophan metabolites. These results elucidate SCFA- and IL-10-independent protective mechanisms exerted by defined resident bacterial strains that are depleted in IBD dysbiosis.

Indexed as

ClostridiumColitisGastrointestinal MicrobiomeMicrobiotaTryptophanAnimalsDisease Models, AnimalDysbiosisFatty Acids, VolatileHumansInflammatory Bowel DiseasesInterleukin-10MiceMice, Inbred C57BLReceptors, Aryl HydrocarbonT-Lymphocytes, RegulatoryFatty Acids, VolatileInterleukin-10Receptors, Aryl HydrocarbonTryptophanaryl hydrocarbon receptordysbiosisEnterobacteriaceaeFusobacteriaindole-3-propionic acidinflammatory bowel diseaseslive biotherapeutic productsmicrobiota-based therapypathobiontprobiotics

Identifiers

PMID42648293
PMCPMC13639900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.